Bloomage Biotech(SH:688363) 智通财经网·2025-09-09 01:47Group 1 - The core viewpoint of the article highlights the significant stock price increase of Saint Noble Pharmaceuticals-B (02257), which has risen over 120% within the month, with a current price of 20.46 HKD and a trading volume of 17.05 million HKD [1] - Saint Noble Pharmaceuticals announced a placement of 17.35 million new shares at a discount of 19.84% to four investors, including Huaxi Biotechnology (Hong Kong) [1] - Huaxi Biotechnology plans to invest approximately 138 million CNY through its wholly-owned subsidiary to acquire shares in Saint Noble Pharmaceuticals, resulting in a 9.44% ownership stake, indicating a shift from being merely a financial investor to a strategic partner [1] Group 2 - The investment aims to significantly advance Saint Noble Pharmaceuticals' research and commercialization efforts in the fields of medical aesthetics, aging intervention, and regenerative medicine [1] - Huaxi Biotechnology will allocate substantial resources towards the STP705 targeted fat reduction project and other siRNA-based medical aesthetic pipeline assets, leveraging clinical research expertise and commercialization capabilities in Greater China and globally [1]